Postscripts Rx
Conversations Beyond the Prescription. Where pharma, HCPs, life science and digital health solutions meets patients—after the script is written. Conversations on digital health, engagement, and real-world impacts that are re-writing the future of patient engagement.
Episodes
38 episodes
When MFN Pricing Meets Patient Power: How Digital Support Becomes the Moat
Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. p...
•
13:06
PBMs, Transparency, and the D2C Pivot
Prices that used to hide in the shadows are stepping into the light—and it’s changing how patients get their medicines. We dive deep into the PBM reckoning: why scrutiny is mounting, how California’s new law opens the books on rebates and reimb...
•
14:54
Inside Pfizer’s Bold Bet on Direct-to-Consumer Drug Sales—and What It Means for Access, Pricing, and Power
A pharmaceutical giant just pressed the D2C button—and the ripple effects could reset how Americans find, pay for, and receive their medications. We unpack Pfizer’s move to list discounted drugs on TrumpRX, why visible pricing matters to patien...
•
12:29
Why Pharma Is Investing Back in the U.S.—And What It Means for Your Medicine
Policy sparks the shift, but patients feel the impact—faster access, steadier supply, and smarter support. We dig into why major pharma players are pouring billions into U.S. manufacturing, how most favored nation pricing is reshaping reimburse...
•
5:45
Why Your Medicine May Soon Say "Made in America"
The pharmaceutical landscape is undergoing a seismic shift as the Trump administration drops a bombshell 100% tariff on imported branded and patented drugs, effective October 1st. This game-changing policy mandates that pharmaceutical companies...
•
13:36
Made in America: Eli Lilly's $6.5B Texas Spend
Pharmaceutical giants are bringing manufacturing back to American soil in a massive strategic pivot. Eli Lilly's recent $6.5 billion investment in a Texas facility for its obesity medications signals a transformative shift that's rapidly spread...
•
11:29
From Hype to Impact: Pharma's 2025-26 Marketing Trends
Curious about where healthcare marketing is heading in the age of AI? Kait Tuson, Founder and CEO of Hello Helio, shares invaluable insi...
•
7:44
How FDA's 2025 DTC Ad Enforcement Reshapes Patient Communication
Pharmaceutical marketing stands at a critical turning point following the FDA and HHS's September 2025 coordinated crackdown on direct-to-consumer prescription drug advertising. This watershed moment marks an unprecedented shift in enforcement,...
•
6:38
'Opti-Channel:' When marketers stop being everywhere and start being where it matters.
The future of pharmaceutical marketing and patient engagement is undergoing a profound transformation. While omnichannel strategies have long been considered the gold standard, promising seamless experiences across all platforms, they've often ...
•
9:52
Puppy Parks and AI Agents: September Pharma Events
Navigating the evolving landscape of pharmaceutical patient support requires staying ahead of emerging technologies and industry trends. In this illuminating conversation with Cathy Zaremba from Medisafe's Marketing team, we dive into key takea...
•
11:23
What Happens When Pharma's TV Ad Boom Goes Bust?
Television networks have developed a dangerous dependency on pharmaceutical advertising dollars, creating a precarious financial ecosystem that few outside the industry fully comprehend. Drug makers poured nearly $3.73 billion into national TV ...
•
9:30
When Markets Shift: Navigating Pharma's UK Strategy Exits
Pharmaceutical giants are abandoning the United Kingdom, and it's sending shockwaves through global healthcare markets. When industry leaders call a major market "uninvestable," every executive needs to pay attention.The stark reality i...
•
8:50
Pharma's $277 Billion Response: Migration to US
The pharmaceutical landscape in America is undergoing a transformation unlike anything we've seen before. When the revised Most Favored Nation (MFN) drug pricing policy dropped in May 2025, few anticipated the tidal wave of strategic responses ...
•
9:37
Transparency at Risk: FDA's Move Away from Advisory Committees
A seismic shift is underway at the FDA that could fundamentally alter how drugs reach American patients. Recent reporting reveals the agency is dramatically scaling back its use of independent advisory committees—consulting external experts on ...
•
10:24
DTC Advertising at Risk? Not So Fast
The pharmaceutical advertising landscape stands at a crossroads as bold new regulatory initiatives threaten to upend decades of established marketing practices. This week, the administration announced plans directing the FDA to reconsider the 3...
•
13:16
FDA's New Crackdown: Balancing Truth in Pharmaceutical Marketing
A seismic shift is underway in pharmaceutical marketing regulation. Yesterday, the FDA fired a warning shot heard across the industry, announcing a massive crackdown on what they're calling misleading pharmaceutical advertising. With over 3,500...
•
15:12
The $250 Billion Response: How MFN Policy Sparked a Pharma Revolution
The pharmaceutical landscape is transforming before our eyes as drug manufacturers respond to the Biden administration's May 2023 Most Favored Nation (MFN) pricing executive order with unprecedented domestic investment. This watershed moment ha...
•
10:23
Fierce Pharma Week - Day 1 Expectations
A quick chat with Medisafe's Ryan Janvion, Stacey Wasserman and Cathy Zaremba on what to expect at Fierce Pharma Week 2025. Industry leaders discuss how hyper-personalization sets true patient engagement apart from the buzzwords that saturate t...
•
2:01
FDA's Domestic Manufacturing Boost: Reshaping Pharma's Future
A seismic shift is underway in pharmaceutical manufacturing. The FDA's newly unveiled Advanced Manufacturing Technologies Designation Program promises to accelerate reviews for facilities producing drugs and biologics on American soil—potential...
•
9:33
Are You Ready When Your Drug Gets Approved Twice as Fast?
Regulatory timelines are changing dramatically, and pharmaceutical companies must adapt or risk being left behind. The Biden administration's pressure on the FDA is yielding concrete results - approval processes that once took 10-12 months are ...
•
10:29
How US Tariffs Are Reshaping UK Pharma Markets
The global pharmaceutical landscape is undergoing a dramatic transformation, with UK pharma feeling the squeeze from US pricing reforms and tariff threats. This episode dives deep into how the 2022 US Inflation Reduction Act has created a domin...
•
11:02
Personalized Patient Engagement: The Future of Pharma
The gap between receiving a prescription and achieving successful treatment outcomes remains one of healthcare's biggest challenges. In this illuminating conversation with Ryan Janvion, VP of Sales and Partnerships at Medisafe, we explore how d...
•
20:47
Beyond the Prescription: Why Supply Chain Security Matters to Everyone
What happens when the medications patients need simply aren't available? The answer is playing out right now across healthcare systems worldwide as pharmaceutical supply chains face unprecedented pressures.The pharmaceutical industry st...
•
9:43
Amgen's $550M US Investment: Reshaping Pharma's Supply Chain and Patient Care
Pharmaceutical manufacturing is undergoing a seismic shift, and Amgen's latest $550 million investment in a cutting-edge biotech research facility in California marks a pivotal moment in this transformation. This bold move signals far more than...
•
11:10
When Prices Equalize, Patient Experience Becomes the Battleground
Healthcare is undergoing a pricing revolution that will fundamentally transform how pharmaceutical companies connect with patients. The new Most Favored Nation model means Medicare will soon pay no more than the lowest price pharmaceutical comp...
•
17:14